Clinical trial · Interventional
Optimal Feeding for NET Patients
Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; a Pilot Study
NCT02481804CI-TRIAL-00076781DIVIT-pilotcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate if optimal personalized consultation by a dietician for a healthy diet focused on food which contains sufficient vitamins and minerals improves gastrointestinal symptoms as determined by an improved score in the gastrointestinal symptoms of the NET specific EORTC QLQ-GINET21 at end of study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumor | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dietary intervention | Other | — | UNRESOLVED |
| Standard treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dietary intervention
- description
- There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
- interventionNames
- Other: Dietary intervention
- Other: Standard treatment
Primary outcomes (1)
- measure
- gastro-intestinal symptoms
- timeFrame
- 18 weeks
- description
- Primary endpoint is the difference in mean gastro-intestinal symptoms score of the EORTC QLQ-GINET21
Secondary outcomes (5)
- measure
- distress
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Adult NET patients (aged ≥ 18 years of age), with serotonine producing or non-serotonin producing tumors, with any tumor site and disease stage. * Use of somatostatin analogue for \> 6 months. * Ability to comprehend Dutch (both reading and writing). * Written informed consent provided. Exclusion Criteria: * Estimated life expectancy less than 3 months. * Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for ≥ 3 years. * Major abdominal surgery during study period. * Known hypersensitivity of (components of) somatostatin analogue.
References
Publications (0)
Data not yet available
No reference posted for this study.